Firouzé Bani‐Sadr
A5089539215- Hepatitis C virus research
- HIV/AIDS drug development and treatment
- Liver Disease Diagnosis and Treatment
- HIV Research and Treatment
- Hepatitis B Virus Studies
- HIV-related health complications and treatments
- HIV/AIDS Research and Interventions
- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- SARS-CoV-2 and COVID-19 Research
- Viral-associated cancers and disorders
- Pneumocystis jirovecii pneumonia detection and treatment
- Antimicrobial Resistance in Staphylococcus
- Orthopedic Infections and Treatments
- HIV, Drug Use, Sexual Risk
- Infectious Diseases and Tuberculosis
- COVID-19 and healthcare impacts
- Immunodeficiency and Autoimmune Disorders
- Hepatitis Viruses Studies and Epidemiology
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Mycobacterium research and diagnosis
- Infective Endocarditis Diagnosis and Management
- Systemic Lupus Erythematosus Research
- Liver Disease and Transplantation
Inserm
2007-2025
Université de Reims Champagne-Ardenne
2016-2025
Centre Hospitalier Universitaire de Reims
2016-2025
Hôpital Robert-Debré
2015-2024
Université Paris Cité
2009-2024
Sorbonne Université
2005-2024
Johns Hopkins Hospital
2024
Sorbonne Paris Cité
2024
Hôpital Bichat-Claude-Bernard
2022-2024
Assistance Publique – Hôpitaux de Paris
2008-2024
Abstract Background The ISARIC prospective multinational observational study is the largest cohort of hospitalized patients with COVID-19. We present relationships age, sex, and nationality to presenting symptoms. Methods International, 60 109 symptomatic laboratory-confirmed COVID-19 recruited from 43 countries between 30 January 3 August 2020. Logistic regression was performed evaluate age sex published case definitions most commonly reported Results ‘Typical’ symptoms fever (69%), cough...
Different neurological manifestations of coronavirus disease 2019 (COVID-19) in adults and children their impact have not been well characterized. We aimed to determine the prevalence in-hospital complications among hospitalized COVID-19 patients ascertain differences between children. conducted a prospective multicentre observational study using International Severe Acute Respiratory emerging Infection Consortium (ISARIC) cohort across 1507 sites worldwide from 30 January 2020 25 May 2021....
Abstract Background Well-established side effects of trimethoprim/sulfamethoxazole include cutaneous and liver toxicity, hypersensitivity syndrome blood dyscrasias. Trimethoprim/sulfamethoxazole has also been associated with severe lung toxicity (LT) but reports are scarce. Methods We investigated pharmacovigilance data reviewed spontaneous trimethoprim/sulfamethoxazole-related LT recorded in the French national database (FPVD) WHO global adverse events (VigiBase®) up to 31 December 2023....
As HIV-infected adults on successful antiretroviral therapy (ART) are expected to have close normal lifespans, they will increasingly develop age-related comorbidities. The objective of this cross-sectional study was compare in the French Dat'AIDS cohort, HIV geriatric population, aged 75 years and over, elderly one, from 50 74 years. Dec 2015, 16,436 subjects (43.8% cohort) were (elderly group) 572 (1.5%) over (geriatric group). Durations infection ART slightly but significantly different,...
Abstract Although it is known that coronavirus disease 2019 can present with a range of neurological manifestations and in-hospital complications, sparse data exist on whether these initial symptoms are closely associated post-acute sequelae SARS-CoV-2 (severe acute respiratory syndrome 2; PANSC) female versus male sex impacts symptom resolution. In this international, multi-centre, prospective, observational study across 407 sites from 15 countries (30 January 2020 to 30 April 2022), we...
To evaluate the incidence, clinical features, and risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus (HCV)-coinfected patients receiving anti-HCV therapy. All cases of reported 416 participating an open, randomized trial peg-interferon alpha-2b plus ribavirin vs. interferon 48 weeks were reviewed. Associations with antiretroviral treatments laboratory findings sought by univariate multivariate analysis. Eleven 383 who received at least 1 dose treatment developed...
To evaluate the prevalence and severity of steatosis possible interactions between steatosis, host factors, viral treatment for HIV infection in HIV-hepatitis C virus (HCV) coinfected patients.Steatosis was assessed among 395 HIV-HCV patients who were enrolled ANRS trial HC02 Ribavic whom histological data available. Steatosis graded as follows: 0 (none); 1 (< 30% hepatocytes containing fat); 2 (30-70%); 3 (> 70%).Steatosis present 241 (61%), 149 (38%) had grade 1, 64 (16%) 28 (7%) 3. In...
In France, it is estimated that 24% of HIV-infected patients are also infected with HCV. Longitudinal studies addressing clinical and public health questions related to HIV-HCV co-infection (HIV-HCV progression its determinants including genetic dimension, patients' experience these two diseases their treatments) limited. The ANRS CO 13 HEPAVIH cohort was set up explore critical questions. To describe the aims organization, monitoring data collection procedures, baseline characteristics, as...
Background. Human immunodeficiency virus (HIV)/hepatitis C (HCV)–coinfected patients with cirrhosis have long been considered to be difficult treat, and real-life efficacy tolerance data all-oral direct-acting antiviral (DAA) combinations in these are scarce. Methods. Cirrhotic HIV/HCV-coinfected enrolled the French National Agency for Research on AIDS Viral Hepatitis (ANRS) CO13 HEPAVIH cohort initiating an DAA regimen were consecutively included. A negative HCV RNA result at 12 weeks of...
Objective: High hepatitis C virus (HCV) treatment uptake combined with effective direct-acting antiviral-based regimens resulted in a dramatic decline of HCV infection French people living HIV (PLWH). We assessed the yearly incidence new PLWH enrolled large Dat'AIDS cohort from 2012 to 2016 specific focus on MSM. Methods: The was determined HCV-negative serological follow-up during 2012–2016. reinfection patients who were cured previous infection. Results: Among 40 714 PLWH, status available...
We compared invasive cervical cancer (ICC) incidence rates in Europe, South Africa, Latin and North America among women living with HIV who initiated antiretroviral therapy (ART) between 1996 2014. analyzed cohort data from the International Epidemiology Databases to Evaluate AIDS (IeDEA) Collaboration of Observational Epidemiological Research Europe (COHERE) EuroCoord. used flexible parametric survival models determine regional ICC risk factors for incident ICC. included 64,231 45...
HIV infection and inflammatory autoimmune diseases (IADs) are both related to immune dysfunction. Epidemiological data on IAD in patients living with (PLHIV) scarce. The aim of this study was thus estimate the prevalence 26 among PLHIV followed a large French multicenter cohort combination antiretroviral therapy (cART) era (from January 2000 July 2013), describe their occurrence according cART onset, immuno-virological status hepatitis C virus (HCV) and/or B coinfection. During period, 33...
The effect of lamivudine on chronic coinfection with hepatitis B virus (HBV) in human immunodeficiency (HIV)--infected patients was studied prospectively. Nineteen HIV infection, who were receiving an anti-HIV regimen containing (150 mg twice daily), and had replicative HBV followed for a median 14 months. Twelve patients' regimens contained protease inhibitors. Serum DNA became undetectable, by means molecular hybridization, 14. Seroconversion e antigen to antibody occurred 6 17 patients,...
Background. We determined the prevalence and determinants of worsening fibrosis in patients coinfected with human immunodeficiency virus (HIV) hepatitis C (HCV) who were receiving anti-HCV therapy.
To analyse the frequency and causes of treatment discontinuation in patients who were treated with an integrase strand transfer inhibitor (INSTI), a focus on neuropsychiatric adverse events (NPAEs). Patients 18 HIV reference centres France prospectively included Dat'AIDS cohort. Data collected from all starting INSTI-containing regimen between 1 January 2006 31 December 2016. All discontinuations analysed, patients' characteristics related to due NPAEs sought. INSTIs prescribed 21315...
Abstract HIV-1 post-treatment controllers are rare individuals controlling infection for years after antiretroviral therapy interruption. Identification of immune correlates control in could aid designing effective vaccine and remission strategies. Here, we perform comprehensive immunoprofiling the humoral response to long-term controllers. Global multivariate analyses combining clinico-virological data reveal distinct profiles experiencing transient viremic episodes off compared those...